Vistagen Therapeutics, Inc. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was USD 0.2777 million compared to negative revenue of USD 0.8925 million a year ago. Net loss was USD 6.59 million compared to USD 17.48 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 2.54 a year ago.
For the six months, revenue was USD 0.4553 million compared to negative revenue of USD 0.5825 million a year ago. Net loss was USD 13.49 million compared to USD 37.26 million a year ago. Basic loss per share from continuing operations was USD 1.55 compared to USD 5.41 a year ago.